Advertisement
UK markets closed
  • FTSE 100

    8,426.12
    +5.86 (+0.07%)
     
  • FTSE 250

    20,859.14
    +109.24 (+0.53%)
     
  • AIM

    810.71
    +16.69 (+2.10%)
     
  • GBP/EUR

    1.1697
    +0.0019 (+0.16%)
     
  • GBP/USD

    1.2706
    0.0000 (-0.00%)
     
  • Bitcoin GBP

    53,022.02
    +398.23 (+0.76%)
     
  • CMC Crypto 200

    1,371.62
    +17.20 (+1.27%)
     
  • S&P 500

    5,319.50
    +16.23 (+0.31%)
     
  • DOW

    40,030.07
    +26.48 (+0.07%)
     
  • CRUDE OIL

    79.86
    -0.20 (-0.25%)
     
  • GOLD FUTURES

    2,427.20
    +9.80 (+0.41%)
     
  • NIKKEI 225

    39,069.68
    +282.30 (+0.73%)
     
  • HANG SENG

    19,636.22
    +82.61 (+0.42%)
     
  • DAX

    18,767.06
    +62.64 (+0.33%)
     
  • CAC 40

    8,197.54
    +30.04 (+0.37%)
     

Medigene AG to present at the 4th TCR-based Therapies for Solid Tumors Summit in Boston

Medigene AG
Medigene AG

Martinsried/Munich, March 28, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the 4th TCR-based Therapies for Solid Tumors Summit in Boston from April 3 to 5, 2023.

On April 4, 2023, Prof. Schendel will first join the Industry Leaders’ Fireside Chat ”What’s Next for T-Cell Receptor Therapies?”, followed by her presentation (see details below).

TCR-based Therapies for Solid Tumors Summit
https://tcr-therapies-summit.com/
Date: April 4, 2023
Presenter: Prof. Dr. Dolores Schendel, CSO
Presentation: Case Study Spotlight: Introducing Innovations at Each Step of TCR-T Therapy Development

Medigene’s management team will be available for one-on-one meetings at the event. Please contact Sandya von der Weid of LifeSci Advisors at svonderweid@lifesciadvisors.com to schedule a meeting.

ADVERTISEMENT

--- end of press release ---

About Medigene
Medigene AG (FSE: MDG1) is a leading immuno-oncology company dedicated to developing T-cell therapies to effectively eliminate cancer. Its end-to-end technology platform, built on multiple proprietary and exclusive product enhancement and product development technologies, allows Medigene to create best-in-class differentiated, t cell receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for both safety and efficacy. This platform provides product candidates for both its in-house therapeutics pipeline and partnering. For more information, please visit www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Medigene

Pamela Keck
Phone: +49 89 2000 3333 01
E-mail: investor@medigene.com

LifeSci Advisors

Sandya von der Weid
Phone: +41 78 680 05 38
E-mail: svonderweid@lifesciadvisors.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.